Life Science Industrial Park - development in Shanghai
Zhangjiang Medical Valley Life Science Industrial Park: facilitating drug discovery and development in Shanghai.
Shanghai has established itself as a leading player in the global life sciences sector with many of local and international pharmaceutical firms using the city as a base for R&D institutes.
As such, the real estate sector has grown steadily and continues to attract investor interest in the aftermath of the Covid-19 pandemic. Since 2021, 20 transactions have taken place.
Simcere Zhoupu Life Science Park in Shanghai is among the recent deals.
The heart of Shanghai’s pharma valley
The 54,466 square meter park was developed by Simcere Pharmaceutical Company in Zhangjiang Zhoupu and serves as its R&D headquarters.
When the company decided to sell, they turned to JLL to facilitate a deal and find a buyer that would understand and protect the specialist nature of the industrial park.
The asset comprises of one main building .and 17 other stand-alone properties, complemented by comprehensive amenities and green features.Tenants in business parks mainly engage in R&D activities related to AI+, innovative drugs and medical equipment.
Simcere Pharmaceutical Company itself is a leading pharmaceutical company in China with more than 6,500 employees.
“Life sciences investors have confidence in the long-term growth prospects of the industry and are interested in assets with anchor tenants or long WALE. Moreover, development opportunities for joint ventures between life sciences companies and investors will arise."
Access to global, specialist investors
JLL’s Life Sciences team immediately tapped into its extensive, global network of investors in this sector and knew that Concora, a subsidiary of Ascent Investment Group's biomedical industrial park business, would appreciate the park’s potential.
Its strategy is to create world-class biomedical industry by buying, developing or repositioning high-quality assets that house research facilities, medical support facilities, biomedical production bases.
Furthermore, Concora supports biopharmaceutical start-ups by forming in-depth partnerships with them, as well as providing additional services to meet the needs of biopharmaceutical tenants through its specialised laboratory and incubator system.
JLL’s global Capital Markets team, with established expertise in Shanghai, quickly facilitated the agreement between the two parties. Simcere Pharmaceutical continues to focus on innovative drug discovery and development in the park while Concora has added an asset to its portfolio that supports its aim of building world-class BioPharma businesses.